摘要
目的了解晚期霍奇金淋巴瘤的治疗效果及影响预后的因素。方法对1999年2月至2011年2月间初治的115例晚期(Ⅲ/Ⅳ期)霍奇金淋巴瘤患者的近期疗效、远期生存及预后因素进行了回顾性总结与分析。结果治疗后完全缓解80.0%(92/115),部分缓解13.9%(16/115),进展6.1%(7/115)。治疗后5年、10年无失败生存与总生存分别为72.2%、68.5%与83.5%、80.9%。单因素分析显示年龄≥45岁,血清β2微球蛋白升高,使用MOPP样化疗方案及化疗未达完全缓解为无失败生存及总生存不良预后因素。此外,血清乳酸脱氢酶升高及国际预后评分≥4分也是总生存不良预后因素。化疗后部分缓解者补充放疗可显著改善无失败生存。多因素分析显示,化疗后未达完全缓解是无失败生存及总生存的独立预后因素。结论本组晚期霍奇金淋巴瘤10年无失败生存与总生存达68.5%与80.9%。预后分析显示,化疗未达完全缓解是影响生存的独立预后因素。
Objective To investigate the survival and prognostic factors for patients with advanced Hodgkin＇s lympho- ma. Method 115 previously untreated patients with histopathologically confirmed stage Ⅲ/Ⅳ Hodgkin＇s lymphoma in our hospital from February 1999 to February 2011 were analyzed for treatment response rates, long-term survival, as well as prognostic factors. Result For the whole group, the rates of complete remission （CR）, partial remission （PR） and disease progression （DP） were 80. 0% , 13.9% and 6 1% , respectively. 5-year and lO-year failure-free survival （FFS） and overall survival （OS） rates were 72. 2% , 68.5% and 83.5% , 80. 9%. Univariate analysis showed that age ≥45, elevated serum β2- microglobulin, chemotherapy regimen MOPP and not achieving CR after the completion of chemothera- py were related to poor FFS and OS; elevated serum lactate dehydrogenase and International Prognostic Score ≥4 were re- lated to poor OS. Irradiation could significantly improve FFS for patients in PR after chemotherapy. Multivariate analysis showed that not achieving CR after chemotherapy was an independent unfavorable prognostic factor influencing FFS and OS.Conclusion The rates of 10-year FFS and OS for patients with advanced Hodgkin＇s lymphoma were 68.5% and 80. 9%. Not achieving CR after chemotherapy is an independent prognostic predictor in advanced Hodgkin＇s lymphoma.
出处
《癌症进展》
2013年第3期259-263,共5页
Oncology Progress
关键词
晚期霍奇金淋巴瘤
近期疗效
远期生存
预后因素
advanced Hodgkin＇s lymphoma
treatment response rates
long-term survival
prognosis
